BRAF and medullary thyroid gland carcinoma: The identification of KRASQ155R as a driver mutation in both FTC and MTC samples, along with other MAPK pathway variants as indicated in Fig. 5B, indicates that while BRAF is not a dominant driver as in humans, the MAPK pathway remains a relevant target for potential therapeutic strategies in canine TC.